A randomized phase 2a trial found the SARS-CoV-2 monoclonal antibody AER002 safe but ineffective for Long COVID overall, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results